U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07103746) titled 'Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy' on July 21.
Brief Summary: This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive immune-mediated necrotizing myopathy.
The primary objective is to estimate the effect of ublituximab as first add-on combination therapy at 24 weeks compared to placebo in treating early, active autoantibody positive immune-mediated necrotizing myopathy using the validated 2016 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Myositis Response Criteria, as measured by the Total...